Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Pivotal Software, Monotype Imaging Holdings, Navigant Consulting, and Genomic Health on behalf of Stockhol...

NEW YORK, Sept. 6, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Pivotal Software, Inc. (NYSE: PVTL), Monotype Imaging Holdings, Inc. (NASDAQ: TYPE), Navigant Consulting, Inc. (NYSE: NCI), and Genomic Health, Inc. (NASDAQ: GHDX).  Additional information about each potential action can be found at the link provided.

Pivotal Software, Inc. (NYSE: PVTL)

Buyer: VMware, Inc.

Pursuant to the proposed transaction, announced on August 22, 2019 and valued at $2.7 billion, Pivotal shareholders of Class A common stock will receive $15 in cash for each share of Pivotal Class A common stock owned.  In addition, Pivotal Class B common stock held by Dell Technologies will be exchanged for 0.0550 shares of VMware Class B common stock.  The investigation focuses on whether Pivotal and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the Pivotal investigation go to:  https://bespc.com/pvtl2/.

Monotype Imaging Holdings Inc. (NASDAQ: TYPE)

Buyer: HGGC

Pursuant to the proposed transaction, announced on July 26, 2019 and valued at $825 million, Monotype shareholders will receive $19.85 in cash for each share of Monotype common stock owned.  The investigation focuses on whether Monotype and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the Monotype investigation go to:  https://bespc.com/type/.

Navigant Consulting, Inc. (NYSE: NCI)

Buyer: Guidehouse

Pursuant to the proposed transaction, announced on August 2, 2019 and valued at $1.1 billion, Navigant shareholders will receive $28 in cash for each share of Navigant common stock owned.  The investigation focuses on whether Navigant and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the Navigant investigation go to:  https://bespc.com/nci/.

Genomic Health, Inc. (NASDAQ: GHDX)

Buyer: Exact Sciences Corporation

Pursuant to the proposed transaction, announced on July 29, 2019 and valued at $2.8 billion, Genomic shareholders will receive $27.50 in cash and the equivalent of $44.50 in shares of Exact common stock for every share of Genomic common stock owned.  The investigation focuses on whether Genomic and its board of directors violated the federal securities laws and/or breached their fiduciary duties to the Company's shareholders by failing to conduct a fair process and whether and by how much the proposed transaction undervalues the Company.

To learn more about the Genomic Health, Inc. investigation go to:  https://bespc.com/ghdx/.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.

View original content to download multimedia:http://www.prnewswire.com/news-releases/bragar-eagel--squire-pc-announces-that-it-is-investigating-the-boards-of-directors-of-pivotal-software-monotype-imaging-holdings-navigant-consulting-and-genomic-health-on-behalf-of-stockholders-and-encourages-investors-to-c-300913481.html

SOURCE Bragar Eagel & Squire, P.C.